SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026)
SAB Biotherapeutics (SABS) posted Enterprise Value of -$107.4 million for Q1 2026, down 11.18% on a QoQ basis from -$96.6 million in Q4 2025, and down 735.71% year-over-year from $16.9 million in Q1 2025.
SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$107.4 million for Q1 2026.
- Quarterly Enterprise Value fell 735.71% year-over-year to -$107.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$107.4 million (down 735.71% YoY) and the FY2025 annual result came in at -$96.6 million, down 365.27% from the prior year.
- Enterprise Value was -$107.4 million for Q1 2026 at SAB Biotherapeutics, down from -$96.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.4 million in Q3 2023 and bottomed at -$110.9 million in Q3 2025.
- A 5-year average of -$35.8 million and a median of -$20.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 1153.39% — and 2025, when it jumped 84.68%.
- SAB Biotherapeutics' Enterprise Value stood at -$15.0 million in 2022, then slumped by 275.93% to -$56.6 million in 2023, then jumped by 63.3% to -$20.8 million in 2024, then tumbled by 365.27% to -$96.6 million in 2025, then decreased by 11.18% to -$107.4 million in 2026.
- Business Quant data shows SABS's Enterprise Value at -$107.4 million in Q1 2026, -$96.6 million in Q4 2025, and -$110.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -107.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.39 Mn |
| Dec 31, 2025 | -96.59 Mn |
| Sep 30, 2025 | -110.88 Mn |
| Jun 30, 2025 | -5.71 Mn |
| Mar 31, 2025 | -12.85 Mn |
| Dec 31, 2024 | -20.76 Mn |
| Sep 30, 2024 | -30.40 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -44.06 Mn |
| Dec 31, 2023 | -56.57 Mn |
| Sep 30, 2023 | -2.43 Mn |
| Jun 30, 2023 | -7.77 Mn |
| Mar 31, 2023 | -13.06 Mn |
| Dec 31, 2022 | -15.05 Mn |
| Sep 30, 2022 | -8.33 Mn |
| Jun 30, 2022 | -16.62 Mn |
| Mar 31, 2022 | -22.41 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -10.75 Mn |
| Jun 30, 2021 | -10.23 Mn |